A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

May 30, 2024

Study Completion Date

June 30, 2026

Conditions
MSI-H Solid Malignant Tumor
Interventions
DRUG

HLX10

HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.

Trial Locations (33)

35002

RECRUITING

the 900th Hospital of Joint Logistic Support Force, Fuzhou

102206

RECRUITING

Peking University International Hospital, Beijing

110042

RECRUITING

Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang

116023

RECRUITING

The Second Affiliated Hospital of Dalian Medical University, Dalian

150040

RECRUITING

Harbin Medical University Cancer Hospital,, Harbin

200065

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

200120

RECRUITING

Shanghai East Hospital, Shanghai

210002

RECRUITING

Qinhuai Medical District, General Hospital of the eastern theater of the Chinese people's Liberation Army, Nanjing

230601

RECRUITING

The Second Affiliated Hospital of Anhui Medical University, Hefei

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

250117

RECRUITING

Shandong Cancer Hospital, Jinan

300060

RECRUITING

Tianjin Medical University Cancer Institue and Hospital, Tianjin

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

318020

RECRUITING

Taizhou first people's Hospital, Taizhou

361003

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

400042

RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

410013

RECRUITING

The Third Xiangya Hospital, Central South University, Changsha

410031

RECRUITING

Hunan Cancer Hospital, Changsha

430062

RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510075

RECRUITING

The First Affiliated Hospital and Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

510080

RECRUITING

The First Affiliated Hospital (School of Clinical Medicine), Guangdong Pharmaceutical University, Guangzhou

510095

RECRUITING

Affiliated Cancer Hospital & Institute, Guangzhou Medical University, Guangzhou

510180

RECRUITING

Affiliated Hospital of Guangdong Medical University, Zhenjiang

519000

RECRUITING

The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai

528010

RECRUITING

First People's Hospital of Fushan, Fushan

528404

RECRUITING

Zhongshan city People's Hospital, Zhongshan

530016

RECRUITING

The People's Hospital of Guangxi Zhuangzu Autonomous Region, Nanning

610041

RECRUITING

Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu

RECRUITING

West China Hospital, Sichuan University, Chengdu

650118

RECRUITING

Yunnan Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Center, Kunming

Unknown

RECRUITING

the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou

050011

RECRUITING

Fourth Hospital of Hebei Medical University,, Shijiazhuang

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY